Takeda Pharmaceutical (TAK) Change in Cash (2018 - 2026)

Takeda Pharmaceutical's Change in Cash history runs 9 years deep, the most recent figure standing at -$388.9 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 40.26% year-over-year to -$388.9 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 378.88% increase from a year earlier, with the FY2026 full-year figure at $1.2 billion, up 389.65% from the prior year.
• Change in Cash fell to -$388.9 million in Q1 2026 per TAK's latest filing, from -$318.4 million in the prior quarter.
• Across five years, Change in Cash topped out at $2.2 billion in Q3 2025 and bottomed at -$2.6 billion in Q4 2024.
• The 5-year median for Change in Cash is -$225.8 million (2025), against an average of -$100.8 million.
• Biggest YoY gain for Change in Cash was 4082.0% in 2024; the steepest drop was 1318.61% in 2024.
• Year by year, Change in Cash stood at -$732.0 million in 2022, then jumped by 75.44% to -$179.8 million in 2023, then slumped by 1318.61% to -$2.6 billion in 2024, then soared by 87.52% to -$318.4 million in 2025, then declined by 22.15% to -$388.9 million in 2026.
• Per Business Quant, the three latest TAK Change in Cash figures stand at -$388.9 million (Q1 2026), -$318.4 million (Q4 2025), and $2.2 billion (Q3 2025).